Anavex Life Sciences Corp
AVXL10.020USD
-0.240-2.34%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
855.83MCap. mercado
PérdidaP/E TTM
Más Datos de Anavex Life Sciences Corp Compañía
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Información de la empresa
Símbolo de cotizaciónAVXL
Nombre de la empresaAnavex Life Sciences Corp
Fecha de salida a bolsaApr 13, 2006
Director ejecutivoDr. Christopher U. Missling, Ph.D.
Número de empleados42
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 13
Dirección630 5Th Avenue
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10111
Teléfono18446893939
Sitio Webhttps://www.anavex.com
Símbolo de cotizaciónAVXL
Fecha de salida a bolsaApr 13, 2006
Director ejecutivoDr. Christopher U. Missling, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.47M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Steffen Thomas, Ph.D.
Dr. Steffen Thomas, Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.47M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
7.24%
The Vanguard Group, Inc.
5.92%
State Street Global Advisors (US)
3.43%
Geode Capital Management, L.L.C.
2.35%
Two Sigma Investments, LP
2.09%
Otro
78.96%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
7.24%
The Vanguard Group, Inc.
5.92%
State Street Global Advisors (US)
3.43%
Geode Capital Management, L.L.C.
2.35%
Two Sigma Investments, LP
2.09%
Otro
78.96%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
23.80%
Investment Advisor/Hedge Fund
9.48%
Individual Investor
3.31%
Hedge Fund
3.04%
Research Firm
1.07%
Bank and Trust
0.83%
Pension Fund
0.22%
Insurance Company
0.04%
Otro
58.22%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
355
34.98M
40.98%
-162.00K
2025Q1
362
35.10M
41.13%
+789.16K
2024Q4
351
32.45M
38.14%
-89.26K
2024Q3
337
29.80M
35.14%
-2.92M
2024Q2
337
29.64M
35.02%
-6.78M
2024Q1
332
34.88M
42.48%
+4.38M
2023Q4
335
28.85M
35.15%
-996.59K
2023Q3
331
28.07M
34.33%
-2.23M
2023Q2
335
28.30M
35.04%
-4.91M
2023Q1
340
29.94M
37.61%
-3.19M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
5.98M
7%
+20.29K
+0.34%
Mar 31, 2025
The Vanguard Group, Inc.
4.88M
5.72%
+202.97K
+4.34%
Mar 31, 2025
State Street Global Advisors (US)
3.21M
3.77%
+802.33K
+33.26%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.96M
2.3%
+89.89K
+4.79%
Mar 31, 2025
Two Sigma Investments, LP
1.37M
1.6%
+100.80K
+7.95%
Mar 31, 2025
Missling (Christopher U)
1.47M
1.72%
--
--
Apr 25, 2025
Skarpelos (Athanasios)
1.31M
1.53%
--
--
Apr 25, 2025
Northwest Asset Management
1.00M
1.17%
+87.30K
+9.56%
Mar 31, 2025
Invesco Capital Management LLC
515.07K
0.6%
-77.48K
-13.08%
Mar 31, 2025
Northern Trust Investments, Inc.
674.75K
0.79%
-26.63K
-3.80%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
